Lawrence H. Baker

Lawrence H. Baker's AcademicInfluence.com Rankings

Lawrence H. Baker

Medical

#2854

World Rank

#3296

Historical Rank

Epidemiology

#545

World Rank

#568

Historical Rank

medical Degrees

Download Badge

Medical

Lawrence H. Baker's Degrees

PhD Epidemiology University of California, Berkeley
Masters Epidemiology University of California, Berkeley
Bachelors Biology University of California, Berkeley

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Lawrence H. Baker Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Lawrence H. Baker's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2009) (2033)
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2011) (999)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. (2008) (942)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. (2017) (728)
Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas (2017) (577)
Integrative Clinical Genomics of Metastatic Cancer (2017) (574)
Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. (1998) (568)
Soft tissue sarcomas of adults: state of the translational science. (2003) (559)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas (2007) (522)
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. (2009) (482)
Comparison of continuously infused 5‐fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma (1975) (413)
Phase II evaluation of adriamycin in human neoplasia (1973) (400)
Malignant melanoma and central nervous system metastases. Incidence, diagnosis, treatment and survival (1978) (380)
Dose response evaluation of adriamycin in human neoplasia (1977) (362)
Chordoma: the nonsarcoma primary bone tumor. (2007) (336)
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. (2007) (313)
Clinical Trials: Design, Conduct, and Analysis (1987) (310)
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. (2011) (287)
Evaluation of cancer information on the Internet (1999) (255)
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial (2011) (255)
Cutaneous angiosarcoma of the scalp (2003) (252)
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. (1980) (249)
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. (2004) (222)
Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. (2012) (222)
Response of extraabdominal desmoid tumors to therapy with imatinib mesylate (2002) (206)
Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide (1972) (204)
Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. (2009) (204)
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. (2000) (201)
Efficacy of Imatinib in Aggressive Fibromatosis: Results of a Phase II Multicenter Sarcoma Alliance for Research through Collaboration (SARC) Trial (2010) (198)
Adriamycin (NSC 123127) used alone and in combination for soft tissue and bony sarcomas (1975) (191)
Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. (1998) (190)
Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. (1990) (172)
Chemotherapy of malignant fibrous histiocytoma. A southwest oncology group report (1977) (162)
Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma (2013) (156)
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes (2003) (148)
Cancer Survivors in the United States: A Review of the Literature and a Call to Action (2012) (147)
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee (2010) (145)
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. (1991) (143)
Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma (2004) (140)
Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy (2005) (140)
Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. (1976) (138)
Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas. (1980) (127)
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701) (2013) (125)
The practicality of chronic hepatic artery infusion therapy of primary and metastatic hepatic malignancies: Ten‐year results of 124 patients in a prospective protocol (1981) (123)
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. (2012) (117)
Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5‐FU vs. methyl‐CCNU plus bolus weekly 5‐FU. A southwest oncology group study (1976) (105)
Molecular alterations of the IDH1 gene in AML: a Children’s Oncology Group and Southwest Oncology Group study (2010) (105)
Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. (2002) (102)
Soft tissue sarcoma. (1999) (100)
NCCN Prostate Cancer Practice Guidelines. The National Comprehensive Cancer Network. (1996) (93)
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor (2017) (88)
Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. (2013) (88)
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. (2013) (86)
Splenic fluorodeoxyglucose uptake increased by granulocyte colony-stimulating factor therapy: PET imaging results. (1999) (86)
Expression of receptor tyrosine kinases epidermal growth factor receptor and HER‐2/neu in synovial sarcoma (2005) (85)
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. (2003) (84)
Phase II study of 9-nitro-camptothecin in patients with advanced chordoma or soft tissue sarcoma. (2005) (82)
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma (2000) (81)
Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development (1992) (80)
Combination chemotherapy using adriamycin, DTIC, cyclophosphamide, and actinomycin D for advanced soft tissue sarcomas: a randomized comparative trial. A phase III, Southwest Oncology Group Study (7613). (1987) (79)
Selection of response criteria for clinical trials of sarcoma treatment. (2008) (79)
Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study. (1987) (77)
SARC009: Phase 2 study of dasatinib in patients with previously treated, high‐grade, advanced sarcoma (2016) (75)
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. (1987) (75)
Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients. (1989) (75)
Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033 (2017) (74)
Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma. (2008) (70)
The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma (2016) (69)
A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST). (2011) (66)
Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. (2008) (66)
Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines (2007) (66)
Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. (2005) (63)
Soft tissue sarcoma clinical practice guidelines in oncology. (2005) (61)
Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts. (2019) (60)
Mitomycin C, Vincristine, and Bleomycin Therapy for Advanced Cervical Cancer (1978) (60)
Prevalence of Hepatitis B Virus, Hepatitis C Virus, and HIV Infection Among Patients With Newly Diagnosed Cancer From Academic and Community Oncology Practices (2019) (57)
Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. (1991) (55)
Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. (2007) (54)
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors (2010) (53)
Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. (2016) (53)
Design of Phase I Combination Trials: Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee (2014) (52)
Discovery of Solid Tumor Active Agents Using a Soft-Agar-Colony-Formation Disk-Diffusion-Assay (1992) (51)
Activity of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF1R), in patients (pts) with recurrent or refractory Ewing's sarcoma family of tumors (ESFT): Results of a phase II SARC study. (2010) (50)
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma. (2012) (49)
Vindesine in patients with metastatic malignant melanoma: a Southwest Oncology Group study. (1984) (48)
The relationship of herpesvirus to carcinoma of the prostate. (1981) (48)
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (46)
Primary versus radiation‐associated craniofacial osteosarcoma (2006) (45)
Difluorodeoxycytidine (dFdC) — gemcitabine: A phase I study (1992) (45)
Is the P388 murine tumor no longer adequate as a drug discovery model? (2004) (45)
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A southwest oncology group study (1993) (42)
Future treatment of soft tissue sarcomas will be driven by histological subtype and molecular aberrations. (2010) (42)
Results of a Sarcoma Alliance for Research through Collaboration (SARC) phase II trial of dasatinib in previously treated, high-grade, advanced sarcoma. (2010) (41)
What Else? Setting the Agenda for the Clinical Interview (2005) (40)
A southwest oncology group and cancer and leukemia group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in Adults with advanced osteosarcoma, ewing's sarcoma, and rhabdomyosarcoma (1998) (39)
Essential erbB family phosphorylation in osteosarcoma as a target for CI‐1033 inhibition (2006) (39)
Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics (2013) (36)
Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. (1978) (35)
Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses. (2017) (35)
Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer (1974) (34)
13-cis-retinoic acid or all-trans-retinoic acid plus interferon-alpha in recurrent cervical cancer: a Southwest Oncology Group phase II randomized trial. (1998) (33)
The natural history of metastatic synovial sarcoma: experience of the Southwest Oncology group. (1982) (33)
Phase II study of profiromycin vs mitomycin-C utilizing acute intermittent schedules. (1976) (33)
Epidermal growth factor receptor expression and mutational analysis in synovial sarcomas and malignant peripheral nerve sheath tumors. (2008) (33)
Ifosfamide and Etoposide in the Treatment of Advanced Soft Tissue Sarcomas (1994) (32)
Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934). (1995) (32)
Multicenter Phase II trial of etoposide in refractory small cell lung cancer. (1985) (32)
Cis-dichlorodiammineplatinum(II) in advanced soft tissue and bony sarcomas: a Southwest Oncology Group Study. (1979) (32)
Antibiotic resistance among Helicobacter pylori clinical isolates in Lima, Peru (2017) (32)
Tumor Models and the Discovery and Secondary Evaluation of Solid Tumor Active Agents (1995) (31)
SARC006: Phase II trial of chemotherapy in sporadic and neurofibromatosis type 1 (NF1)-associated high-grade malignant peripheral nerve sheath tumors (MPNSTs). (2013) (30)
Phase II study of 5-azacytidine in solid tumors. (1977) (30)
How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. (2011) (30)
Adriamycin and 5-fluorouracil in the treatment of advanced hepatoma: a Southwest Oncology Group study. (1977) (30)
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib (2018) (27)
Primary Cardiac Sarcoma: A Rare, Aggressive Malignancy with a High Propensity for Brain Metastases (2019) (27)
Phase I evaluation and clinical pharmacology of tricyclic nucleoside 5'-phosphate using a weekly intravenous regimen. (1986) (27)
The value of serial carcinoembryonic antigen (CEA) in predicting response rate and survival of patients with gastrointestinal cancer treated with chemotherapy. A Southwest oncology group study (1979) (27)
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. (2015) (26)
Treatment of six cases of mesothelioma with doxorubicin and cisplatin (1983) (26)
Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma (2013) (26)
Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer. (1976) (26)
Alterations in plasma sialyltransferase associated with successful chemotherapy of a disseminated tumor. Case report (1976) (25)
Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. (1978) (25)
Gallium nitrate in malignant lymphoma: a Southwest Oncology Group study. (1983) (25)
Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme (2006) (25)
Response of chronic myelogenous leukemia patients to COAP—splenectomy. A southwest oncology group study (1984) (23)
Prioritization in Comparative Effectiveness Research: The CANCERGEN Experience (2012) (22)
Medical and pediatric oncology, not adult and pediatric oncology. (2005) (22)
Response to Early Treatment Evaluated with 18F-FDG PET and PERCIST 1.0 Predicts Survival in Patients with Ewing Sarcoma Family of Tumors Treated with a Monoclonal Antibody to the Insulinlike Growth Factor 1 Receptor (2016) (22)
VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary. (1978) (22)
A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. (2006) (22)
Second-line treatment of advanced measurable ovarian cancer with iproplatin: a Southwest Oncology Group study. (1991) (22)
Anticancer Drug Discovery and Development: Natural Products and New Molecular Models (1994) (21)
Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT). (2012) (21)
Next generation sequencing of extraskeletal myxoid chondrosarcoma (2017) (21)
Modeling the Relationship between Progression-Free Survival and Overall Survival: The Phase II/III Trial (2013) (21)
Phase II study of mitomycin‐C, vincristine, and bleomycin in advanced squamous cell carcinoma of the uterine cervix (1976) (21)
Small round cell sarcomas (2009) (21)
Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study (1988) (20)
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma (2007) (20)
Phase II study of AMSA in lung cancer. (1981) (20)
Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group (2016) (20)
SARC 028: A phase II study of the anti-PD1 antibody pembrolizumab (P) in patients (Pts) with advanced sarcomas. (2015) (20)
Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer (2004) (19)
Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. (1975) (19)
A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS) (2005) (19)
Phase II Trial of Cetuximab in Patients With Metastatic or Locally Advanced Soft Tissue or Bone Sarcoma (2013) (19)
Phase I clinical trial of combined therapy with vinblastine (NSC-49842), bleomycin (NSC-125066), and cisdichlorodiammineplatinum(II)( NSC-119875). (1976) (19)
Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. (2003) (18)
The future of sarcoma treatment. (1997) (18)
Phase II trial cisplatin, doxorubicin, and cyclophosphamide (CAP) in the treatment of urothelial transitional cell carcinoma. (1981) (18)
Systemic adjuvant chemotherapy for soft tissue sarcomas. (1995) (18)
A phase i‐ii study of maytansine utilizing a weekly schedule (1980) (18)
Adjuvant Therapy for Soft Tissue Sarcomas (1988) (18)
Moving a randomized clinical trial into an observational cohort (2013) (18)
Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. (2006) (18)
Phase I trial of Adozelesin using the treatment schedule of daily × 5 every 3 weeks (1995) (17)
New in vitro screening model for the discovery of antileukemic anticancer agents. (1996) (17)
Reduced infectivity of waterborne viable but nonculturable Helicobacter pylori strain SS1 in mice (2017) (17)
Phase I study of oral mitomycin C. (1976) (17)
Epidemiological findings in a brain-tumor cluster in western Missouri. (1985) (17)
Gastrointestinal stromal tumors: Chemotherapy and imatinib (2002) (16)
Systemic Adjuvant Chemotherapy for Soft Tissue Sarcomas of the Extremities (1993) (16)
A useful high‐dose intermittent schedule of adriamycin and DTIC in the treatment of advanced sarcomas (1986) (16)
Nonepithelial malignancies of the breast. (2004) (15)
Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study. (1983) (15)
Erratum: Essential erbB family phosphorylation in osteosarcoma as a target for CI‐1033 inhibition (2013) (15)
Randomized Phase III Trial of Chemoimmunotherapy in Patients with Previously Untreated Stages III and IV Suboptimal Disease Ovarian Cancer: A Southwest Oncology Group Study (1989) (15)
Phase I trial of spiromustine (NSC 172112) and evaluation of toxicity and schedule in a murine model. (1987) (14)
Bony metastasis from adenocarcinoma of the colon. (1974) (14)
A SARC multicenter phase III study of gemcitabine (G) vs. gemcitabine and docetaxel (G+D) in patients (pts) with metastatic soft tissue sarcomas (STS). (2006) (14)
Phase I-II clinical trial of gallium nitrate (NSC-15200). (1980) (14)
Phase I--II study of intermittent bolus administration of DTIC and actinomycin D in metastatic malignant melanoma. (1978) (14)
Clinical pharmacokinetics of high-dose mitomycin C (2004) (14)
Assessment of Imaging Modalities and Response Metrics in Ewing Sarcoma: Correlation With Survival. (2016) (14)
Fludarabine Phosphate Phase II Evaluation in Advanced Soft‐Tissue Sarcomas (1987) (14)
Phase I evaluation and pharmacokinetics of aziridinylbenzoquinone using a weekly intravenous schedule. (1983) (13)
Mitomycin C and bleomycin in the treatment of far-advanced cervical cancer: a Southwest Oncology Group pilot study. (1980) (13)
Reevaluation of rebound regression in disseminated carcinoma of the breast (1972) (13)
A Southwest Oncology Group phase II trial of recombinant tumor necrosis factor in metastatic breast cancer (1991) (13)
Preliminary experiences with intra-arterial adriamycin. (1977) (12)
Phase II evaluation of dianhydrogalactitol in lung cancer: a Southwest Oncology Group Study. (1981) (12)
Phase II trial of tamoxifen in malignant melanoma. (1982) (12)
Phase I study of echinomycin. (1987) (11)
Alteration of dacarbazine pharmacokinetics after interleukin-2 administration in melanoma patients (2004) (11)
Magnetic Resonance in Experimental and Clinical Oncology (1990) (11)
Gallium nitrate in advanced soft tissue and bone sarcomas: a Southwest Oncology Group Study. (1982) (11)
Phase II evaluation of chlorozotocin (NSC-178248) in advanced human cancer. (1981) (10)
Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. (2012) (10)
Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial (2004) (10)
Treatment options for muscle‐invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (2008) (10)
Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice (2004) (10)
Phase II clinical trial of ftorafur in 5-fluorouracil-refractory colorectal cancer. (1977) (10)
High‐dose cisplatin for metastatic soft tissue sarcoma (1990) (10)
CBDCA: Phase II Evaluation in Advanced Colorectal Carcinoma (1987) (10)
CISPLATIN IN TREATMENT OF CERVICAL AND ENDOMETRIAL CANCER PATIENTS (1980) (9)
Gardner's syndrome in a 40-year-old woman: successful treatment of locally aggressive desmoid tumors with cytotoxic chemotherapy (2006) (9)
Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005. (2010) (9)
Treatment of six cases of mesothelioma with doxorubicin and cisplatin. (1983) (9)
American experience with carminomycin. (1979) (9)
Antitumour activity of N-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9H-thioxanthen-4-yl]methyl]methanesulfonamide (WIN33377) and analogues (1994) (9)
Phase II Trial of Merbarone in Pancreatic Carcinoma: A Southwest Oncology Group Study (1993) (9)
Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas (2021) (9)
Use of VM-26 as a single agent in the treatment of renal carcinoma. (1979) (8)
Myxoid Malignant Fibrous Histiocytoma with Multiple Primary Sites (2002) (8)
Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma. (1982) (8)
Pharmacokinetics of 9-methoxy-N,N-dimethyl-5-nitropyrazolo [3,4, 5-kl]acridine-2(6H)-propanamine (PZA, PD 115934, NSC 366140) in mice: guidelines for early clinical trials1. (1995) (8)
Activity of imatinib mesylate in desmoid tumors: Interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. (2004) (8)
Combination chemotherapy in the management of disseminated soft tissue sarcomas - A southwest oncology group (SWOG) study (1979) (8)
Phase I and II evaluation of cytembena in disseminated epithelial ovarian cancers and sarcomas. (1976) (8)
Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study. (1983) (7)
Cancer Survivorship-A Call to Action. (2020) (7)
Reversed-phase high-performance liquid chromatographic determination of tricyclic nucleoside and tricyclic nucleoside 5'-phosphate in biological specimens. (1985) (7)
Advances in the chemotherapy of soft tissue sarcomas. (1977) (7)
Evaluation of gallium nitrate in metastatic or locally recurrent squamous cell carcinoma of the head and neck: a Southwest Oncology Group study. (1984) (7)
Metastatic Dedifferentiated Chordoma With Elevated &bgr;-hCG: A Case Report (2002) (6)
A comparative study of mitomycin-C and porfiromycin (1974) (6)
Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008 (2009) (6)
Differential Outcomes and Biologic Markers of Radiation-Associated vs. Sporadic Osteosarcoma: A Single-Institution Experience (2020) (6)
Vindesine in patients with metastatic malignant melanoma. (A swog study) (1982) (6)
Biochemical Modulation of Anticancer Agents: Experimental and Clinical Approaches (2011) (6)
The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. (2016) (6)
Available data from carminomycin studies in the United States: the acute intermittent intravenous schedule. (1981) (6)
Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. (1984) (6)
Chromomycin A3 for advanced breast cancer: a Southwest Oncology Group study. (1978) (6)
Chemotherapy for metastic osteosarcoma--studies by the M.D. Anderson Hospital and the Southwest Oncology Group. (1978) (6)
Ecteinascidin-743 is a potent inhibitor of P450 3A4 enzyme and accumulates cytoplasmic PXR to inhibit transcription of P450 3A4 and MDR1: Implications for the enhancement of cytotoxicity to chemotherapeutic agents in osteosarcoma (2005) (6)
5-FU infusion and cyclophosphamide in the treatment of advanced ovarian cancer. (1977) (6)
Pharmacotherapy of sarcoma (2009) (5)
9404 ORAL Long-term Survival on S0033 – a Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate at Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumours (GISTs) (2011) (5)
High‐Dose Mitomycin‐C with Autologous Bone Marrow Transplantation in Patients with Refractory Malignancies Influence of Dose Schedule on Pharmacokinetics and Nonhematopoietic Toxicities (1986) (5)
Aclacinomycin A Phase II Evaluation in Advanced Soft Tissue Sarcoma (1987) (5)
Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study (2018) (5)
Gene Therapy of Human Breast Cancer. (1998) (5)
Phase II evaluation of dianhydrogalactitol (DAG) in treatment of advanced sarcoma and malignant melanoma (1977) (5)
Imatinib mesylate in soft tissue and bone sarcomas: Interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. (2004) (5)
Treatment of non-small cell bronchogenic carcinoma with vinblastine and mitomycin: a Southwest Oncology Group Study. (1985) (5)
Phase I-II study of DTIC and cyclocytidine in disseminated malignant melanoma (1976) (5)
Phase I trial of aclacinomycin-A (2004) (5)
Mitomycin C, vincristine and bleomycin in disseminated squamous cell cancer of the uterine cervix (1977) (5)
Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma. (2011) (5)
PCNU in advanced adenocarcinoma of the ovary: a phase II study. (1983) (5)
Adriamycin and single dose dtic in soft tissue and bone sarcomas (1982) (4)
Response of patients with carcinoma of the breast to hormonal therapy and combination chemotherapy. (1975) (4)
Phase II trial of methyl‐GAG (NSC‐32946) in squamous cell and adenocarcinoma of the lung (1982) (4)
Phase II evaluation of gallium nitrate in breast cancer: a Southwest Oncology Group Study. (1982) (4)
A Randomised Trial of empiric 14-day Triple, five-day Concomitant, and ten-day Sequential Therapies for Helicobacter pylori in Seven Latin American Sites (2016) (4)
Letter: Multiple myeloma. (1975) (4)
Combination chemotherapy with mitomycin C, adriamycin, and cyclophosphamide in advanced adenocarcinoma and large cell carcinoma of the lung. (1979) (4)
A Randomized Trial Comparing 14-Day Triple, 10-Day Sequential, and 5-Day Concomitant Therapy to Eradicate Helicobacter pylori in Seven Latin American Populations (2011) (4)
Phase II trial of recombinant human macrophage colony-stimulating factor in metastatic soft tissue sarcoma. (1994) (4)
Prediction of early pulmonary toxicity due to bleomycin (BLEO) in cancer patients treated with combination therapy (1977) (4)
High-dose cisplatin for metastatic soft tissue sarcoma. (1990) (4)
Phase I study and pharmacokinetics of caracemide (NSC-253272) administered as a short infusion (1987) (4)
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors (2012) (4)
Burden of chronic diseases among sarcoma survivors treated with anthracycline chemotherapy: results from an observational study (2020) (4)
Dibromodulcitol (DBD), DTIC, and actinomycin‐D in disseminated malignant melanoma A phase I‐II clinical trial (1985) (4)
Phase I Clinical Trial of Pyrazoloacridine N 5 C 366140 ( PD 115934 ) ’ (2005) (4)
Clinical trial of rubidazone in advanced squamous cell carcinoma of the lung and adenocarcinoma of the large intestine. (1978) (4)
Phase II study of high-dose intermittent cycloleucine in colorectal malignancies. (1982) (3)
High-performance liquid chromatographic determination of nafazatrom in human plasma using fluorescence detection. (1984) (3)
Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: a Southwest Oncology Group Study. (1987) (3)
High‐dose ifosfamide with mesna and granuloctye–colony‐stimulating factor (recombinant human G‐CSF) in patients with unresectable malignant mesothelioma (2003) (3)
Phase II evaluation of aclacinomycin‐A in patients with adenocarcinoma and large cell carcinoma of the lung (1985) (3)
Drug Discovery — 1990 (1992) (3)
Combination chemotherapy with mitomycin C, adriamycin, and cyclophosphamide (MAC) in stage III and IV ovarian cancer. (1983) (3)
Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. (2011) (3)
Detoxification ability and toxicity of quinones in mouse and human tumor cell lines used for anticancer drug screening (2004) (3)
Phase II evaluation of 1-(2-chloroethyl)-3-(2,6-dioxo-(piperidyl)-1 nitrosourea (PCNU)(NSC-95466) in patients with advanced carcinoma of the lung. (1983) (3)
Development of a Queriable Database for Oncology Outcome Analysis (2008) (2)
SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies (2011) (2)
1046 Predictors of Success of Helicobacter pylori Eradication Treatment in a Multicentric Randomized Clinical Trial (SWOG S0701) in Latin America (2012) (2)
Su1673 H. pylori Recurrence One Year After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven Latin American Sites (2012) (2)
Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: a Southwest Oncology Group Study. (1989) (2)
Phase I and pharmacologic evaluation of nafazatrom in patients with cancer (2004) (2)
Protocol performance metrics and resource utilization of phase II investigator-initiated trials. (2010) (2)
Aclacinomycin A Phase II Evaluation in Bronchogenic Squamous‐Cell Carcinoma (1987) (2)
Phase II trial of diaziquone in advanced large bowel carcinoma in previously treated and untreated patients: a Southwest Oncology Group Study. (1985) (2)
Acodazole hydrochloride: phase I trial, pharmacokinetics, and evaluation of cardiotoxicity in dogs. (1988) (2)
Genomic Profiling of Cancers of Unknown Primary Site: The Next Steps. (2015) (2)
Dibromodulcitol (DBD), DTIC (D) and actinomycin D (A) in metastatic malignant melanoma (1982) (2)
Crisnatol mesylate: Phase I dose escalation by extending infusion duration (1991) (2)
Phase I trial of ftorafur combined with mitomycin C or methyl-CCNU in gastrointestinal cancers. (1977) (2)
SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy (2016) (2)
Chlorozotocin (CZT) (NSC-178248): Phase II trial (1979) (2)
Combination chemotherapy with cyclophosphamide, vincristine, methyl-CCNU, and bleomycin in advanced bronchogenic carcinoma: experience with 106 patients. (1977) (2)
Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028. (2017) (2)
High dose mitomycin c (MMC) and autologous bone marrow transplantation. Clinical results and pharmacokinetics (1982) (2)
Soft tissue sarcoma (1999) (1)
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers). (2012) (1)
Early treatment response by FDG PET in patients with the Ewing sarcoma family of tumors predicts survival (2013) (1)
Phase II trial of dianhydrogalactitol in advanced renal cell carcinoma: a Southwest Oncology Group study. (1982) (1)
Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer. (1978) (1)
Intermittent bolus administration of DTIC and actinomycin-D in metastatic malignant melanoma (1978) (1)
Prevalence of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV) among newly diagnosed cancer patients treated in academic and community oncology practices: SWOG S1204. (2018) (1)
Expression of HER 2 / Neu ( HER 2 ) and EGFR In Osteosarcoma ( Os ) (2003) (1)
Evaluation of beta-2'-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer. A Southwest Oncology Group study. (1981) (1)
Phase II trial of intravenous melphalan for metastatic colorectal carcinoma. A Southwest Oncology Group study. (1990) (1)
New Drugs for the Treatment of Soft Tissue Sarcomas (1980) (1)
Comparing current care to the NCCN prostate cancer practice guidelines (1999) (1)
Recent concepts in sarcoma treatment : proceedings of the International Symposium on Sarcomas, Tarpon Springs, Florida, October 8-10, 1987 (1988) (1)
5 Fluorouracil and adriamycin therapy for hepatoma (1976) (1)
Bone cancer clinical practice guidelines. (2005) (1)
Evaluation of cardiovascular health in sarcoma survivors. (2017) (1)
Prepare and plan for financial constraints on clinical trials. (2007) (1)
A comparative trial of cis-platinum (C) oncovin (O) and bleomycin (B) vs. methotrexate (M) in patients with advanced epidermoid carcinomas of the head and neck (1979) (1)
Su1677 Risk Factors for Helicobacter pylori Infection in Six Latin American Countries (SWOG Trial S0701) (2012) (1)
Phase II clinical evaluation of AZQ in adenocarcinoma of the lung (1984) (1)
Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer. (1974) (1)
Pharmacokinetics of ifosfamide and cytochrome P450 3A in a phase II trial of doxorubicin and ifosfamide in sarcoma patients (2005) (1)
Systematic evaluation of risk factors for acquired heart disease in sarcoma survivors. (2017) (1)
Colon cancer: medical therapy. (1988) (1)
The necessity for rigour in rare disease study design. (2019) (1)
Anal canal and esophageal squamous cell carcinomas: the role of combined modality treatment (1987) (1)
Phase II evaluation of cycloleucine in the treatment of patients with disseminated sarcomas. (1981) (1)
Phase II trial of intravenous melphalan for metastatic colorectal carcinoma (2004) (1)
Docetaxel enhances S-phase cytotoxicity with dFdCyd resulting in synergy (2004) (1)
The who and what of imaging in sarcoma and correlation with survival. (2015) (1)
Expression and activity of PXR target genes CYP3A4 and MDR1 in sarcoma tumors predict response to chemotherapeutic agents (2004) (0)
Introduction to 5-FU symposium (1989) (0)
Running Title : Mitochondrial fatty acid synthase 1 Discovery and characterization of the 3-hydroxyacyl-ACP dehydratase component 2 of the plant mitochondrial fatty acid synthase system 3 (2017) (0)
PCNU: Phase II evaluation in advanced colorectal carcinoma (1988) (0)
Phase II trial of menogaril in adenocarcinoma of the pancreas (1991) (0)
Investigational Drug Steering Committee Trial Design Task Force of the National Cancer Institute Therapeutics : Consensus Recommendations from the Clinical The Design of Phase II Clinical Trials Testing Cancer (2010) (0)
Phase II study of combination of BCNU and DTIC in the treatment of advanced relapsing lymphomas (1978) (0)
Final Report : DAMD 1794-J-4385 " Gene Therapy of Human Cancer " (0)
Radiation-associated versus sporadic osteosarcoma: A single-institution experience. (2017) (0)
599 POSTER Epidermal Growth Factor Receptor (EGFR) Expression and Mutational Analysis in Synovial Sarcomas and Malignant Peripheral Nerve Sheath Tumors (2006) (0)
Abstract B37: Evaluation of cardiovascular and musculoskeletal health in sarcoma survivors (2018) (0)
Breast cancer screening. Evaluation of Kansas program data. (1983) (0)
Abstract B16: Dystrophin is a tumor suppressor in peripheral nerve sheath tumors (2018) (0)
Phase II evaluation of rubidazone (NSC-164011) in advanced carcinoma of the breast (2004) (0)
Symptom assessment in patients with cancer of unknown primary site. (2015) (0)
Pharmacokinetics of cycloleucine (1979) (0)
Pathology (2001) (0)
Short communication Response rates - an evolution (1994) (0)
Phase I-II trial of adriamycin (AD) and 5 fluorouracil (FU) (1977) (0)
Response rates — An evolution (1994) (0)
Biology and Therapy of Acute Leukemia (1985) (0)
Additional file 1: of SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy (2016) (0)
PCN82 RESEARCH PRIORITIZATION FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)
In reply [4] (2006) (0)
Contemporary Concerns in Managing Bone Sarcoma. (2016) (0)
590 One-Year Effectiveness and Costs of Six Alternative H. pylori Test/Treat and Retest/Retreat Strategies Using Triple, Concomitant or Sequential Drug Regimens in Seven Latin American Sites (SWOG Trial S0701) (2012) (0)
New agents for sarcoma. (2007) (0)
Adriamycin bladder instillation (ABI) for prophylaxis and treatment of N [4 (5 nitro 2 furyl) 2 thiazolyl] formamide (FANFT) induced bladder cancer (1976) (0)
Erratum: Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines (Cancer (2007) 109 (957-965)) (2013) (0)
An orthotopic model of human osteosarcoma using two isogenic cell lines differing in their ability to form spontaneous pulmonary metastasis (2007) (0)
Abstract 25: Targeting c-Myc in pediatric sarcoma xenografts with the BET bromodomain inhibitor, JQ1, disrupts angiogenesis (2014) (0)
276 INVITED IGF1R Inhibitors in the Treatment of Ewing Sarcomas (2011) (0)
Abstract208: Outcomes After Combined Modality Treatment of Retroperitoneal Sarcomas (2006) (0)
Phase II trial of ftorafur (Ft) with mitomycin c (MMC) or with methyl CCNU (Me) in colon cancer (1977) (0)
Radiation Associated Angiosarcoma: a Single Institution Case Series and Tissue Microarray (2005) (0)
Abstract SY26-02: SWOG S0701 phase III randomized trial of three antibiotic regimens to eradicate helicobacter pylori: efficacy and failure at one year (2012) (0)
NCCN practice guidelines: Bone cancers (1999) (0)
Thanks to authors and peer reviewers (2008) (0)
ROC analysis of varying PET metrics to predict survival in patients with Ewing sarcoma family of tumor (2013) (0)
Cytochrome P 450 C YP3A4/5 E xpression a s a B iomarker o f Outcome i n O steosarcoma (2003) (0)
Inferior vena cava leiomyosarcoma: A single-institution experience. (2018) (0)
Mitomycin C, vincristine and bleomycin in treatment of advanced cancers (1974) (0)
12 – GYNECOLOGICAL CANCERS (1981) (0)
Phase I evaluation of aclacinomycin A (NSC-208734) in a weekly I.V. schedule (1981) (0)
Problems in the Clinical Evaluation of Biochemical Modulation Therapy (1986) (0)
Low-dose, continuous infusion 5-fluorouracil and oral etoposide for the treatment of advanced sarcomas. (1995) (0)
Machine Learning Approaches in Bioinformatics and Computational Biology (2004) (0)
Chemotherapy of Disseminated Soft Tissue Sarcomas (1983) (0)
Comprehensive genomic profiling in malignant myoepithelioma to suggest potential alternative diagnosis. (2020) (0)
Cancer Survivorship-Considering Mindsets-Reply. (2020) (0)
Clinical Trial Designs for the 21st Century: What are adaptive designs and what role do they play in SWOG's future? (2010) (0)
Clinical trial of rubidazone in lung and colon carcinoma (1978) (0)
Biology and therapy of acute leukemia : proceedings of the Seventeenth Annual Detroit Cancer Symposium, Detroit, Michigan, April 12-13, 1984 (1985) (0)
Not all progressive metabolic diseases on PET are equal in patients with relapsed or refractory sarcoma (2013) (0)
Response to “A Porsche for Patient Accrual,” by David Steinberg, Cancer Investigation, 2005, 23(8), pp. 741–743 (2006) (0)
Sarcomas: the role of adjuvant chemotherapy and a proposed new staging system. (1996) (0)
Phase 1-11 study of DTIC and cyclocytidine in disseminated malignant melanoma. (1976) (0)
SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy (2016) (0)
399 Constitutive erbB family phosphorylation in osteosarcoma as a target for CI 1033 inhibition (2004) (0)
Serum carcinoembryonic antigen levels and the response to chemotherapy in gastrointestinal tumors (1975) (0)
In Memoriam: Charles A. Coltman, 1930 to 2018. (2019) (0)
Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study. (1991) (0)
In Memoriam: Charles A. Coltman, 1930 to 2018. (2019) (0)
Phase II study of diaziquone in advanced soft tissue and bony sarcoma: a Southwest Oncology Group study. (1985) (0)
A comparison of outcomes, presentation, and treatment in pediatric (Ped) versus adult patients (Pts) with Ewing sarcoma. (2018) (0)
Change in hottest tumor location following treatment on FDG PET in patients with Ewing sarcoma: A marker of poor prognosis (2013) (0)
A Structured Approach to Prioritizing Cancer Research Using Stakeholders and Value of Information (2018) (0)
Abstract 3145: Detection of premature aging among adolescent and young adult osteosarcoma and Ewings sarcoma survivors (2019) (0)
HIPP: A heterogeneity and irregularity parameter based on PERCIST for FDG PET imaging with prognostic value (2013) (0)
Impact of value of research analyses on SWOG’s clinical trial capsule scoring. (2017) (0)
Clinical response and pharmacokinetics of aziridinylbenzoquinone (AZQ) in solid peripheral and CNS tumors (1982) (0)
Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701) (2012) (0)
Generic sirolimus: a future opportunity to decrease the cost of oncology care? (2013) (0)
Late relapse in soft tissue sarcoma: Prognostic factors for recurrence after 3 years. (2014) (0)
PCN12 HORIZON SCANNING TO SUPPORT PRIORITY-SETTING FOR PROSPECTIVE COMPARATIVE EFFECTIVENESS RESEARCH (CER) IN CANCER GENOMICS (2010) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Lawrence H. Baker?

Lawrence H. Baker is affiliated with the following schools:

Lawrence H. Baker's Academic­Influence.com Rankings